Health AI Central
Peer-Reviewed Publication
Am J Prev Cardiol2026;30101739.December 1, 2026Journal Article

Real-world treatment adherence and persistence among patients initiating inclisiran or PCSK9 mAbs.

Robert S Rosenson1, Xiaoli Niu2, Lyuba Popadic3, Xinshuo Ma3, Pam Kumparatana3, Yuqin Wei3, Yousuf Ali2, Sean McElligott2
1Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
3Komodo Health, Inc., San Francisco, CA, USA.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.